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EditorialA Great MatchIt is hard to believe that the International Society for Stem Cell
Research (ISSCR) is 10 years old, and that coincident with this
is the fifth-year anniversary ofCell StemCell. Having participated
in the creation and development of the society and the journal,
the success of both has made me appreciate my matchmaking
skills.
When I founded the ISSCR, I was responding to a call from
stem cell researchers to bring investigators together and form
a community. The annual meeting served this purpose from its
fledgling initial meeting in Washington, D.C., with about 550
people, to this year’s meeting in Yokohama with about 4,000
individuals. There is a tremendous need for scientific interac-
tions, and the community is vibrant and operates at a very high
level.
One of my initial thoughts for the ISSCR was that it needed
a journal. A key driver was the stem cell research community’s
call for a dedicated forum to publish stem cell research and to
discuss issues faced by the field—a high-quality and high-visi-
bility journal to give the field credibility and capture the highest
profile papers. In this endeavor, after a long negotiation, we affil-
iated with Cell Press to start Cell Stem Cell. I am pleased to have
been integral in the discussions that resulted in the strong part-
nership between ISSCR and Cell Stem Cell.
Cell StemCell has accomplished all of its goals admirably from
its initiation, and Debbie Sweet has been a pioneering editor with
great vision. With a 2010 impact factor of 25.9, it is clearly a high-
end journal that publishes impactful papers. The reviews are
fantastic and comprehensive. The ISSCR section of the journal
is one of its unique features, presenting key undertakings of
the society such as committee activities, task force initiatives,
and professional guidance. The ISSCR meeting reviews are
greatly welcomed.
When Cell Stem Cell needed to become nimble, decisions
were made to create new sections that reflect the progress in
the field. I am particularly interested in the Clinical Progress
section that allows data to be put into the journal that bridges
basic research and clinical application. There is also a diversity
of articles in Cell Stem Cell. This includes the tremendous litera-
ture on induced pluripotent stem cells (a field in itself and one
that will greatly contribute to science and medicine in the future).
The journal, in short, has been a great success, has had wonder-
ful interactions with the ISSCR, and has moved the field forward
in a palpable and self-renewing manner.
The ISSCR has tackled many issues in its first 10 years. One of
the most important aspects was mentoring. It is clear that young
investigators have found a home in the ISSCR. The society has
a special committee for junior investigators and there is a formal
mentoring session at each annual meeting. I remember the time
period before induced pluripotent stem cells were available
when young investigators were unclear if any funding would be
available for human pluripotent stem cell studies on the only
available technology, human embryonic stem cells. It was hard
to have the courage to start a lab working on pluripotent cells,
and now with many advances, the field is vibrant with many
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including having Laurie Zoloth make a presidential session
speech at one of the annual meetings. The society has also
made a strong effort to reach out to patient advocates and
policy-makers, and few will forget the powerful speech that
one such advocate, Charles Sabine, gave at the 2011 meeting.
The ethics of working with stem cells were brought to the fore-
front because of a Presidential executive order. Many of us
from the leadership of the ISSCR have appeared on radio, on
TV, and in other contexts to inform and educate the public about
stem cell research.
The stem cell field has also had to deal with some difficult
issues over the past 10 years. We found out that human cloning
was not in fact performed in Korea despite prior publication. In
Europe, a landmark legal decision about patenting of human
embryonic stem cells changed the landscape for future research
and commercial development. U.S. researchers weathered
considerable uncertainty when a judicial process based on
a lawsuit brought by investigators who do not support research
on embryonic stem cells shut down federal funding for a period
of time. The society responded by defining its role in embryonic
stem cell research (a role that not everyone in the field embraces,
but one that is practical and informative). At this point, it seems
as though embryonic stem cells are becoming less of a ‘‘big
issue’’ and there is broader recognition that they are important
for the future of the field. In vitro fertilization was once a huge
source of ethical disagreement, but is now mainstream. I hope
that embryonic stem cells will achieve a similar status.
The ISSCR has also provided information and expert opinions
to helpmany governments address their stem cell issues. As part
of that effort, the society produced an international document on
the practical use and ethical use of stem cells. In addition, coun-
seling of individual governments facilitated the set-up of stem
cell institutes in various countries. Government policy has been
strongly influenced by the advice of several ISSCR presidents
and leaders.
The public efforts of the ISSCR revolve around a single topic
chosen every year by the president. In my case, I focused on
education of the public. More recently, there has been a decision
to examine questionable clinics that do stem cell research. Such
‘‘snake oil salesmen’’ often promise major clinical success for
therapies that are not scientifically based. The society is in the
process of evaluating how to call out companies that are
involved in such efforts and how to inform the public of such
behavior. In the interim, we have created a web page to provide
information to patients who seek to evaluate new stem cell ther-
apies (http://www.closerlookatstemcells.org).
It has been interesting to watch the leadership transitions that
occur through the ISSCR. Each year a new president takes the
helm and brings their unique perspective to the role. Greg
Schultz, the founding executive director, was absolutely critical
in the process in the early days, and Nancy Witty, our current
executive director, has done a wonderful job over the past 6
years. It is clearly through Nancy’s leadership that the mission
of the ISSCR has been truly executed.
Cell Stem Cell
EditorialI see a number of future opportunities for the field of stem
cell research and regenerative medicine in which the ISSCR
and Cell Stem Cell can play a vital role. One of those is clin-
ical translation. Existing successes include limbal stem cells
being transplanted to treat corneal eye diseases and the
expansion of blood stem cells. The study of patient-specific
induced pluripotent stem cells or ‘‘diseases in a dish’’ will
undoubtedly yield information that will be brought to the clinic.
The need for a facilitation of this process is very important
and a journal is critical. I feel that Cell Stem Cell could have
a pioneering role in promoting translation of stem cell
research. There are many issues yet to be overcome,
including ones related to safety, manufacturing, and access
to stem cell treatments.
Another issue for the field is to maintain the quality of the
research it produces. With the increasing number of researchers
getting involved, it is critical to remain rigorous, and to ensure
that published conclusions are well supported by data. The field
has already seen its share of retractions and controversy. I hope
that everyone working in this area will continue to producefantastic research that builds to a crescendo of clinical
relevance.
Here is what I said at the very first meeting at the end of my
presidential speech:
‘‘I am very enthusiastic about the Society, and I hope that
20 years from now we will be utilizing stem cells in the
clinic as routine medical therapy for many genetic and
degenerative disorders, that the basic genetics and
molecular biology and cell biology of the stem cell will
be largely understood, and that the Society will be filled
with wonderful young trainees and old investigators such
as myself.’’
We are now at the halfway mark, celebrating the ISSCR’s 10th
Annual Meeting where we are hearing a wealth of progress
towards this goal, presented by a truly global community of all
ages.
I want to raise a toast to ISSCR and Cell Stem Cell: to a happy
birthday and continued success.
Leonard I. Zon
Founding President, ISSCR
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